[LCID Study Number: 20193133]
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
This is a multi-center study of XMT-1536 in patients with tumors likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and non-small cell lung cancer. The primary objective is to determine the maximum tolerated dose or recommended Phase 2 dose of a once every 4-week administration of XMT-1536 and to assess the safety and tolerability of XMT-1536.
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3421